Sun Pharmaceutical Industries Acquires Concert Pharmaceuticals

Sun Pharma Acquires Checkpoint Therapeutics

May 30, 2025

Biotechnology

Sun Pharmaceutical Industries Limited has completed the acquisition of Checkpoint Therapeutics, Inc., acquiring all outstanding shares for $4.10 per share in cash plus a contingent value right. The deal gives Sun Pharma ownership of UNLOXCYT (cosibelimab-ipdl), the FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma, and expands its oncology/onco-derm product portfolio.

Pfizer Acquires Arena Pharmaceuticals

December 13, 2021

Pharmaceuticals

Pfizer Inc. agreed to acquire clinical-stage Arena Pharmaceuticals for $100 per share in an all-cash transaction valued at approximately $6.7 billion, creating a wholly owned subsidiary. The acquisition brings Arena's development-stage portfolio — including etrasimod and cardiovascular assets — into Pfizer's Inflammation & Immunology pipeline to accelerate clinical development and expand therapeutic capabilities.

MorphoSys Acquires Constellation Pharmaceuticals for $1.7B

June 2, 2021

Biotechnology

MorphoSys AG has agreed to acquire Constellation Pharmaceuticals for $34.00 per share in cash, valuing the transaction at approximately $1.7 billion. The deal strengthens MorphoSys' hematology-oncology pipeline by adding Constellation's mid- to late-stage candidates (pelabresib/CPI-0610 and CPI-0209) and is supported by a strategic funding partnership with Royalty Pharma that provides significant upfront and milestone funding.

Pfizer Acquires Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Pharmaceuticals

Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for approximately $11.6 billion (at $148.50 per share), bringing the migraine therapy NURTEC ODT (rimegepant), the zavegepant NDA program, and a CGRP-focused pipeline into Pfizer's Internal Medicine portfolio. Prior to closing, Biohaven spun off its non-CGRP assets into a separate publicly traded company, Biohaven Ltd., which Pfizer received a small pro rata stake in.

Concentra Biosciences (Tang Capital) to Acquire Theseus Pharmaceuticals

December 22, 2023

Biotechnology

Concentra Biosciences, a vehicle controlled by Tang Capital Partners, has entered into a definitive merger agreement to acquire clinical-stage biotech Theseus Pharmaceuticals for $3.90–$4.05 per share in cash plus a contingent value right tied to future program licensing/disposition proceeds. The transaction will be effected by a tender offer and is expected to close in February 2024, subject to customary conditions and the availability of required cash at closing.

Assertio Holdings Acquires Spectrum Pharmaceuticals

April 25, 2023

Pharmaceuticals

Assertio Holdings, Inc. agreed to acquire all outstanding shares of Spectrum Pharmaceuticals, Inc. in an all-stock transaction with contingent value rights (CVRs), expected to close in Q3 2023. The deal combines Assertio's digital, non-personal commercial capabilities with Spectrum's in-person commercial team and ROLVEDON (eflapegrastim-xnst) to accelerate the product's launch and broaden the combined company's pharmaceutical portfolio.